Group
EGFR targeting TKI
The data below refer to patients treated with EGFR targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Afatinib
Erlotinib
Gefitinib
Icotinib
Lazertinib
Osimertinib
Dacomitinib
No data
Mobocertinib
No data
Sunvozertinib
No data